TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02733549

Intervention type: OTHER
Intervention: LFTs
Description: A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed.

Intervention type: OTHER
Intervention: LFTs
Description: A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed.
Study: NCT03138551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mealtime PREP (Promoting Routines of Exploration and Play)
Study: NCT03896854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19 cells/kg).
Study: NCT04112771

Intervention type: DRUG
Intervention: Penehyclidine hydrochloride
Description: Penehyclidine hydrochloride was administered before anesthesia induction.

Intervention type: OTHER
Intervention: No penehyclidine hydrochloride
Description: Penehyclidine hydrochloride was not administered before anesthesia induction.
Study: NCT01018693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAK694; Alutard Avanz SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAK694 placebo infusion; Alutard Avanz SQ
Study: NCT01097096

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAD106
Description: 150μg and 450μg doses were reconstituted and administered via intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAD106
Description: 150μg and 450μg doses were reconstituted and administered via intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAD106
Description: 150μg and 450μg doses were reconstituted and administered via intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAD106
Description: 150μg and 450μg doses were reconstituted and administered via intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAD106
Description: 150μg and 450μg doses were reconstituted and administered via intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAD106
Description: 150μg and 450μg doses were reconstituted and administered via intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo to CAD106 administered via intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo to CAD106 administered via intramuscular injection
Study: NCT01018693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAK694 placebo infusion; Saline
Study: NCT01607294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 Daily for 4 weeks
Study: NCT01097096

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo to CAD106 administered via intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alum
Description: An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alum
Description: An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59
Description: An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59
Description: An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59
Description: An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59
Description: An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59
Description: An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59
Description: An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106
Study: NCT01607294

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Daily for 4 weeks
Study: NCT01998152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Patients in the intervention-arm will receive individualized nutritional counseling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.
Study: NCT00294827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation and colo-rectal cancer
Description: Liver transplantation
Study: NCT04307173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL693
Description: Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL693
Description: Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral
Study: NCT01977729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S\<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
Study: NCT04089527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-95775
Description: CC-95775
Study: NCT03268889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
Study: NCT00271908

Intervention type: BEHAVIORAL
Intervention: Community Mobilization
Description: ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus.

Intervention type: BEHAVIORAL
Intervention: Community Mobilization
Description: ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus.
Study: NCT03813875

Intervention type: DRUG
Intervention: Fentanyl
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0\~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
Study: NCT00214487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bifocal Contact Lenses
Description: Use of bifocal contact lenses of varying add powers to control the progression of myopia

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Single vision soft contact lenses
Study: NCT00812604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ping On Ointment
Description: Ping On Ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: Placebo
Study: NCT04687488

Intervention type: OTHER
Group type: OTHER
Intervention: Fluorescein
Description: For droplet visualization, we will use fluorescein, which has been used for many years in medicine for diagnostic purposes and is safe upon topical administration, as a tracer. There are no local or systemic side effects of topical sodium fluorescein (5). Fluorescein is routinely used in the mouth to stain dental plaque (6). Through the lacrimal duct, the nasal cavity is exposed to fluorescein when it is used for ophthalmological purposes (7). Allergic reactions have been described to intravenous injection, which is not part of our trial. In the setting of head-and-neck and otolaryngological surgeries, coating the mouth with fluorescein has been used to quantify droplet spread, to assess for risk of transmission of COVID-19 (8). Hence, fluorescein can be safely applied to nasal and oropharyngeal cavities. We will use a similar approach, coating the nasal cavity, to study droplet spread from the nose during naso-gastric intubation for motility or reflux testing.

Intervention type: OTHER
Group type: OTHER
Intervention: Particle measurement
Description: Quantification of aerosol will be done using a medical particle counter, as used for hospital safety measurements.
Study: NCT01414517

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FructoOligoSaccharide
Description: A mixture of 70% oligofructose and 30% inulin.
Study: NCT01414517

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: a non-prebiotic carbohydrate
Study: NCT01586936

Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Prescription of eptacog alpha at the discretion of the physician
Study: NCT00700986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056
Description: Oral tablet, 800mg, one single administration
Study: NCT03813875

Intervention type: DRUG
Intervention: sevoflurane
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0\~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.

Intervention type: DRUG
Intervention: midazolam
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0\~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
Study: NCT02118454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily IVR Calls Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly IVR Survey Only
Study: NCT04113356

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance Imaging
Description: Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
Study: NCT01643408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase Erwinia chrysanthemi
Study: NCT03366025

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum progesterone measure
Description: Serum Progesterone will be measured in all donors on the day triggering at 8:00 am, 12:00 p, 16:00 pm and 20:00 pm
Study: NCT01194219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Identical matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Identical matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical treatments or phototherapy
Description: At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
Study: NCT02343601

Intervention type: DEVICE
Group type: OTHER
Intervention: Photoplethysmography
Description: Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
Study: NCT02630069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP-choline
Description: CDP-choline 500mg once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500mg once a day for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Description: Supportive psychotherapy 1 session/2 weeks for 12 weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive psychotherapy
Description: Supportive psychotherapy 1 session/2 weeks for 12 weeks
Study: NCT01457664

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to RO4995819 once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4995819
Description: RO4995819 doses once daily for 14 days
Study: NCT05365516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementing medical safety huddles
Description: These short, virtual huddles are led by a huddle leader and occur on a weekly or once every two week basis. Each site will be adapting the Medical Safety Huddles for their context and workflow to specifically engage physicians.
Study: NCT03685318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of conventional mouthguard
Description: Use of a conventional custom-made mouthguard while playing water polo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of shortened mouthguard
Description: Use of a shortened custom-made mouthguard while playing water polo
Study: NCT01206634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative injection therapy
Description: Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
Study: NCT01158755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
Study: NCT03689608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting (IF)
Description: Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Restriction (DR)
Description: Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: standard care (SC)
Description: Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.
Study: NCT03108092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRIP intervention
Description: The STRIP intervention consists of 9 steps: 1. structured history taking of medication 2. recording medication and diagnoses in STRIPA 3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria 4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation 5. shared decision-making with the patient with possible adaptation of the recommendation 6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions) 7. generation of general practioner (GP) report 8. delivery of the report to the patient and to the GP (optional additional direct communication) 9. follow-up

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Standard care in the department where the trial is conducted
Study: NCT01288053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Therapy
Description: Donor stem cells will be given to subject diagnosed with Crohn's disease
Study: NCT01476592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
Study: NCT03484117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.
Study: NCT00997568

Intervention type: DEVICE
Intervention: PET-511BTM
Description: Transesophageal Transducer
Study: NCT02377518

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media
Study: NCT03202979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone 20 mg
Description: Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.~After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone 10 mg
Description: Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.~In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions.
Study: NCT00700986

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose